Eurogentec and Exiqon in Licensing Agreement | GenomeWeb

NEW YORK, March 19 -- Eurogentec of Sart-Tilman, Belgium, today announced a non-exclusive licensing agreement to manufacture and sell modified oligonucleotides produced with Exiqon's locked nucleic acid technology.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.